It was recently demonstrated that POLE mutations affecting only proofreading could predict anti–PD-1 efficacy in mismatch repair–proficient tumors revealing POLE proofreading deficiency as a new tissue-agnostic biomarker for cancer immunotherapy (Rousseau et al, 2022). This evidence concerns the gene POLE and cancer.